• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患者内他克莫司浓度变异性高可预测肾移植受者慢性组织学病变的加速进展。

High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients.

机构信息

Department of Microbiology and Immunology, KU Leuven - University of Leuven, and Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium.

Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven - University of Leuven, Leuven, Belgium.

出版信息

Am J Transplant. 2016 Oct;16(10):2954-2963. doi: 10.1111/ajt.13803. Epub 2016 Apr 21.

DOI:10.1111/ajt.13803
PMID:27013142
Abstract

High intrapatient variability (IPV) of tacrolimus concentrations is increasingly recognized as a predictor of poor outcome in solid organ recipients. How it relates to evolution of histology has not been explored. We analyzed tacrolimus IPV using the coefficient of variability (CV) from months 6-12 after transplantation in a cohort of 220 renal recipients for whom paired protocol biopsies at 3 mo and 2 years were available. Recipients in the highest CV tertile had an increased risk of moderate to severe fibrosis and tubular atrophy by 2 years compared with the low-IPV tertile (odds ratio [OR] 2.47, 95% confidence interval [CI] 1.09-5.60, p = 0.031; and OR 2.40, 95% CI 1.03-5.60, p = 0.043, respectively). Other predictors were donor age, severity of chronic lesions at 3 mo, and presence of borderline or subclinical rejection at 3 mo. Chronicity score increased significantly more in the high CV tertile group than in the middle and low tertiles (mean increase 1.97 ± 2.03 vs. 1.18 ± 2.44 and 1.12 ± 1.80, respectively; p < 0.05). CV did not predict evolution of renal function, which did not deteriorate within the 2-year follow-up period. These results indicate that high IPV is related to accelerated progression of chronic histologic lesions before any evidence of renal dysfunction.

摘要

高个体内变异度(IPV)的他克莫司浓度越来越被认为是实体器官受者预后不良的预测指标。但其与组织学演变的关系尚未得到探索。我们分析了 220 名肾移植受者队列中 6-12 个月时的他克莫司 IPV,这些受者有 3 个月和 2 年时的配对方案活检。与低 IPV 三分位组相比,CV 最高三分位组在 2 年内发生中度至重度纤维化和肾小管萎缩的风险增加(比值比 [OR] 2.47,95%置信区间 [CI] 1.09-5.60,p = 0.031;OR 2.40,95%CI 1.03-5.60,p = 0.043)。其他预测因素包括供体年龄、3 个月时慢性病变的严重程度和 3 个月时边界或亚临床排斥反应的存在。高 CV 三分位组的慢性评分显著高于中三分位和低三分位组(平均增加 1.97 ± 2.03 比 1.18 ± 2.44 和 1.12 ± 1.80;p < 0.05)。CV 不能预测肾功能的演变,在 2 年的随访期内肾功能没有恶化。这些结果表明,高 IPV 与肾功能障碍任何证据之前慢性组织学病变的加速进展有关。

相似文献

1
High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients.患者内他克莫司浓度变异性高可预测肾移植受者慢性组织学病变的加速进展。
Am J Transplant. 2016 Oct;16(10):2954-2963. doi: 10.1111/ajt.13803. Epub 2016 Apr 21.
2
Clinical significance of tacrolimus intra-patient variability on kidney transplant outcomes according to pre-transplant immunological risk.根据移植前免疫风险,他克莫司患者内个体差异对肾移植结局的临床意义。
Sci Rep. 2021 Jun 9;11(1):12114. doi: 10.1038/s41598-021-91630-4.
3
Late intra-patient tacrolimus trough level variability as a major problem in kidney transplantation: A Collaborative Transplant Study Report.患者个体内他克莫司谷浓度变异性大是肾移植中的一个主要问题:协作移植研究报告。
Am J Transplant. 2019 Oct;19(10):2805-2813. doi: 10.1111/ajt.15346. Epub 2019 Apr 10.
4
Renal Allograft Histology at 10 Years After Transplantation in the Tacrolimus Era: Evidence of Pervasive Chronic Injury.移植后 10 年的肾移植组织病理学:普遍慢性损伤的证据。
Am J Transplant. 2018 Jan;18(1):180-188. doi: 10.1111/ajt.14431. Epub 2017 Aug 18.
5
Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study.降低低免疫风险肾移植受者的缓释他克莫司剂量会增加排斥反应风险及供者特异性抗体的出现:一项随机研究。
Am J Transplant. 2017 May;17(5):1370-1379. doi: 10.1111/ajt.14109. Epub 2017 Jan 3.
6
Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.贝利尤单抗联合短期钙调磷酸酶抑制剂治疗可预防排斥反应并促进长期移植物肾功能改善。
Am J Transplant. 2017 Nov;17(11):2922-2936. doi: 10.1111/ajt.14353. Epub 2017 Jul 3.
7
Tacrolimus intrapatient variability in BK virus nephropathy and chronic calcineurin toxicity in kidney transplantation.他克莫司在肾移植中导致的 BK 病毒肾病和慢性钙调磷酸酶抑制剂毒性的患者内变异性。
Saudi J Kidney Dis Transpl. 2021 Mar-Apr;32(2):348-354. doi: 10.4103/1319-2442.335446.
8
Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values.评估稳定依从性移植受者中环孢素的个体内变异性:建立基线值。
Am J Transplant. 2019 May;19(5):1410-1420. doi: 10.1111/ajt.15199. Epub 2018 Dec 26.
9
Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients.钙调磷酸酶抑制剂(他克莫司)撤药在长期稳定肾移植受者中的随机试验失败。
Am J Transplant. 2016 Nov;16(11):3255-3261. doi: 10.1111/ajt.13946. Epub 2016 Jul 29.
10
Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.依维莫司联合低剂量他克莫司与霉酚酸酯联合标准剂量他克莫司用于初治肾移植受者的疗效和安全性:12个月数据
Am J Transplant. 2017 May;17(5):1358-1369. doi: 10.1111/ajt.14090. Epub 2017 Jan 4.

引用本文的文献

1
The predictive value of tacrolimus intrapatient variability and time in therapeutic range for renal transplant outcomes.他克莫司患者内变异性及治疗范围内时间对肾移植结局的预测价值。
Ren Fail. 2025 Dec;47(1):2549395. doi: 10.1080/0886022X.2025.2549395. Epub 2025 Sep 3.
2
Impact of Tacrolimus Trough Levels at Discharge on Early Post-Kidney Transplantation Outcomes: A Nationwide Cohort Study.出院时他克莫司谷浓度对肾移植术后早期结局的影响:一项全国性队列研究
J Clin Med. 2025 Aug 12;14(16):5707. doi: 10.3390/jcm14165707.
3
Prediction of postoperative infection through early-stage salivary microbiota following kidney transplantation using machine learning techniques.
利用机器学习技术通过肾移植术后早期唾液微生物群预测术后感染
Ren Fail. 2025 Dec;47(1):2519816. doi: 10.1080/0886022X.2025.2519816. Epub 2025 Jul 3.
4
Intrapatient tacrolimus variability is associated with medical nonadherence among pediatric kidney transplant recipients.小儿肾移植受者体内他克莫司的个体差异与药物治疗依从性差有关。
Front Transplant. 2025 Mar 17;4:1572928. doi: 10.3389/frtra.2025.1572928. eCollection 2025.
5
Erratic tacrolimus levels at 6 to 12 months post-lung transplant predicts poor outcomes.肺移植术后6至12个月他克莫司水平不稳定预示着预后不良。
JHLT Open. 2023 Dec 13;3:100043. doi: 10.1016/j.jhlto.2023.100043. eCollection 2024 Feb.
6
Intrapatient variability of tacrolimus trough level may be not the cause, but an indirect parameter of comorbidities: Editorial on "Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation".他克莫司谷浓度的患者内变异性可能并非病因,而是合并症的一个间接参数:关于“降低慢性肾脏病风险的他克莫司最佳水平以及患者内变异性对肝移植后慢性肾脏病和终末期肾病发展的影响”的社论
Clin Mol Hepatol. 2025 Apr;31(2):589-591. doi: 10.3350/cmh.2025.0076. Epub 2025 Jan 24.
7
Patiromer Does Not Alter Tacrolimus Pharmacokinetics in Kidney Transplant Recipients When Administered Three Hours Post-Tacrolimus.在肾移植受者中,于他克莫司给药三小时后给予帕替罗姆不会改变他克莫司的药代动力学。
Transplant Direct. 2024 Nov 14;10(12):e1733. doi: 10.1097/TXD.0000000000001733. eCollection 2024 Dec.
8
Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation.降低慢性肾脏病风险的他克莫司最佳水平以及肝移植后患者体内药物浓度变异性对慢性肾脏病和终末期肾病发生发展的影响。
Clin Mol Hepatol. 2025 Jan;31(1):131-146. doi: 10.3350/cmh.2024.0451. Epub 2024 Oct 2.
9
The Influence of Tacrolimus Exposure and Metabolism on the Outcomes of Kidney Transplants.他克莫司暴露及代谢对肾移植结局的影响。
Biomedicines. 2024 May 18;12(5):1125. doi: 10.3390/biomedicines12051125.
10
Tacrolimus's Time Below Therapeutic Range Is Associated With Acute Pancreatic Graft Rejection and the Development of Donor-specific Antibodies.他克莫司治疗窗浓度以下与急性胰腺移植物排斥和供体特异性抗体的产生有关。
Transpl Int. 2024 Apr 17;37:12591. doi: 10.3389/ti.2024.12591. eCollection 2024.